HER2-Mutant NSCLC Clinical Trial Landscape

Key trials in HER2-mutant NSCLC

The HER2-mutant NSCLC pipeline is among the most active in all targeted lung cancer therapy as of 2026. The table below reflects recruiting trials as of early 2026; DataLookout monitors ClinicalTrials.gov daily for new registrations and status changes.

Sources: ClinicalTrials.gov. DataLookout monitors for new registrations and status updates daily. Table reflects recruiting trials as of early 2026. 12+ HER2-mutant NSCLC trials are actively recruiting globally.

HER2 mutations in NSCLC: biology, epidemiology, and historical context

HER2 (ERBB2) is a receptor tyrosine kinase in the ErbB family, most famous for its role in breast cancer where amplification or overexpression drives approximately 15–20% of tumors. In NSCLC, the relevant alteration is different: activating somatic mutations in the HER2 kinase domain, predominantly exon 20 insertions, which lock the kinase in a constitutively active conformation. HER2 exon 20 insertions occur in approximately 2–3% of NSCLC, translating to an estimated 10,000–15,000 new patients per year in the United States alone.

The most common HER2 exon 20 insertion is A775_G776insYVMA, accounting for approximately 20–30% of all HER2 exon 20 insertions in lung cancer. Other common insertions include P780_Y781insGSP and G778_P780dup. The insertion site within exon 20 may influence both the degree of kinase activation and the structural accessibility of the ATP-binding pocket to different TKI chemotypes, a consideration that has driven selectivity engineering in drugs like zongertinib and NVL-330.

T-DXd (Enhertu): the first approved therapy for HER2-mutant NSCLC

Trastuzumab deruxtecan (T-DXd, Enhertu) is an antibody-drug conjugate (ADC) developed jointly by Daiichi Sankyo and AstraZeneca. It consists of a trastuzumab antibody (targeting HER2 extracellular domain), a cleavable tetrapeptide linker, and a topoisomerase I inhibitor payload (DXd, a derivative of exatecan). T-DXd exploits a "bystander effect", the released payload can diffuse into neighboring cells, providing activity even in tumors with heterogeneous HER2 expression.

T-DXd's approval represented a paradigm shift in HER2-mutant NSCLC, before it, no targeted agent had achieved consistent ORRs above ~30% in this setting. Previous attempts with pan-HER TKIs (afatinib, neratinib, dacomitinib) and HER2 antibodies (trastuzumab, pertuzumab) had largely failed, leading to skepticism about targetability of HER2 mutations in lung cancer. The DESTINY-Lung02 results demonstrated that the ADC mechanism, delivering a cytotoxic payload to HER2-expressing cells regardless of the specific mutation, could overcome the kinase-selectivity challenges of small-molecule TKIs.

T-DXd ILD: a critical safety consideration

Interstitial lung disease (ILD) / pneumonitis is the most clinically significant adverse event associated with T-DXd across tumor types. In DESTINY-Lung02, drug-related ILD occurred in 26% of patients at 6.4 mg/kg and 12% at the approved 5.4 mg/kg dose, with 2 fatal ILD events at the higher dose. Active monitoring for ILD is mandatory in T-DXd-treated patients: CT chest imaging at baseline and periodic intervals, prompt investigation of any new respiratory symptoms, and appropriate dose modification or discontinuation. Oncologists managing NSCLC patients on T-DXd must have established protocols for ILD surveillance and management.

Zongertinib (BI 1810631): the oral TKI challenging T-DXd

Zongertinib (Boehringer Ingelheim) is a next-generation, irreversible, highly selective HER2-targeted TKI designed to address the major limitation of earlier pan-HER TKIs in HER2-mutant NSCLC: EGFR wild-type toxicity. Pan-HER TKIs like afatinib, neratinib, and poziotinib inhibit both EGFR and HER2, causing dose-limiting diarrhea and rash through EGFR inhibition in the GI tract and skin. Zongertinib's selectivity profile, potent HER2 inhibition with sparing of EGFR wild-type, is intended to enable a tolerable therapeutic index at doses sufficient for clinical efficacy.

Beamion LUNG-2 (NCT06151574): Phase 3 registration trial

Beamion LUNG-2 is a global Phase 3 randomized trial comparing zongertinib versus standard of care (which includes T-DXd and chemotherapy as options) in previously treated advanced HER2-mutant NSCLC. This is the first Phase 3 trial directly comparing an oral HER2 TKI against T-DXd, and its results will define whether selective oral TKI therapy can match or exceed the efficacy of the approved ADC in the second-line setting. If positive, zongertinib would become the first oral targeted therapy specifically approved for HER2-mutant NSCLC in the post-platinum second-line setting.

Beamion LUNG-3 (NCT07195695): adjuvant setting

Beamion LUNG-3 is a Phase 3 adjuvant trial comparing zongertinib versus standard treatment (including observation or chemotherapy) following complete surgical resection of HER2-mutant NSCLC. This trial mirrors the adjuvant development path in ALK+ NSCLC (lorlatinib ALINA), EGFR-mutant NSCLC (osimertinib ADAURA), and ROS1+ NSCLC (taletrectinib TRUST-IV). Given the OS benefit demonstrated by adjuvant osimertinib in EGFR-mutant NSCLC, the hypothesis that adjuvant targeted TKI therapy can prevent recurrence in HER2-mutant NSCLC is well-supported by analogy.

Competing HER2-targeted agents in Phase 3

Sevabertinib (BAY 2927088, Bayer)

Sevabertinib is an oral, selective HER2/EGFR inhibitor in development by Bayer for HER2-mutant NSCLC. It selectively targets mutant EGFR (exon 20 insertions) and HER2 (exon 20 insertions) while sparing EGFR wild-type, a similar selectivity engineering approach to zongertinib. Phase 1/2 data showed an ORR of ~53% in pretreated HER2-mutant NSCLC, motivating the Phase 3 SOLSTICE trial (NCT06452277) comparing sevabertinib versus standard of care. The competitive dynamics between sevabertinib, zongertinib, and T-DXd will define second-line HER2-mutant NSCLC treatment over the next 2–3 years.

SHR-A1811 (Jiangsu HengRui)

SHR-A1811 is a HER2-targeted ADC developed by HengRui Medicine, incorporating a topoisomerase I inhibitor payload similar to T-DXd but with a potentially differentiated linker-payload system. A Phase 3 trial (NCT06430437) is comparing SHR-A1811 versus standard first-line therapy in HER2-mutant NSCLC, an earlier line of therapy than T-DXd's current approved indication (previously treated). If positive, SHR-A1811 could establish an ADC as the preferred first-line therapy for HER2-mutant NSCLC, analogous to how T-DXd has transformed the second-line setting.

Next-generation agents: NVL-330 and beyond

Nuvalent, the company developing neladalkib (ALK) and NVL-520 (ROS1), has also entered the HER2-mutant NSCLC space with NVL-330, a highly selective HER2-targeted TKI in Phase 1 development (HEROEX-1, NCT06521554). Nuvalent's engineering approach, which has produced some of the most selective and CNS-penetrant kinase inhibitors in oncology, is now being applied to HER2, particularly targeting HER2 exon 20 insertions with the selectivity-for-mutant-over-wild-type profile that has differentiated the company's ALK and ROS1 programs.

BlossomHill Therapeutics' BH-30643 and Pierre Fabre's STX-721/PFL-721 represent additional entrants targeting both EGFR and HER2 exon 20 insertions, reflecting the structural similarity between these two alterations and the opportunity to develop drugs active against both subgroups simultaneously. Given that EGFR exon 20 insertions (amivantamab-approved) and HER2 exon 20 insertions are biologically related but clinically distinct, dual-targeting agents face a complex regulatory and commercial path.

HER2-mutant vs. HER2-amplified vs. HER2-overexpressing NSCLC: three distinct populations

The HER2 landscape in NSCLC involves three molecularly distinct populations that respond differently to anti-HER2 therapies, and which are the subject of separate clinical programs:

• HER2 exon 20 insertions (~2–3% of NSCLC): The primary focus of this page. Activating kinase domain mutations. T-DXd approved; zongertinib and sevabertinib in Phase 3.
• HER2 amplification (~3–6% of NSCLC): Gene copy number increase, often without mutation. Generally lower HER2 protein levels than breast cancer. Sensitivity to T-DXd and TKIs is less predictable than for mutations. Active investigation in T-DXd combination trials.
• HER2 overexpression (IHC 3+, ~7–15% of NSCLC): High protein expression without necessarily harboring mutations or amplification. T-DXd is being studied in Phase 3 trials (NCT06899126) for first-line HER2-overexpressing NSCLC, an indication distinct from the approved HER2-mutant label.

These distinctions matter for clinical trial eligibility, regulatory strategy, and commercial planning. A drug approved for HER2-mutant NSCLC (mutation-driven) has a different label and patient population than one approved for HER2-overexpressing NSCLC. Pharma teams monitoring this space should track all three populations separately while recognizing their biological overlap.

Related clinical trials and monitoring resources

HER2-mutant NSCLC is part of the broader targeted therapy revolution in lung cancer, with particularly close connections to EGFR exon 20 biology. DataLookout monitors related areas including:

• NSCLC clinical trials: full non-small cell lung cancer pipeline, all molecular subgroups
• EGFR mutant lung cancer clinical trials: largest NSCLC targeted therapy population; exon 20 insertions share biological features with HER2 exon 20
• ALK-positive lung cancer clinical trials: parallel TKI development trajectory; Nuvalent active in both ALK and HER2
• ROS1-fusion NSCLC clinical trials: another rare (~1–2%) targetable NSCLC subgroup; Nuvalent active in ROS1 and HER2
• RET-fusion NSCLC clinical trials: comparative rare oncogene subgroup; similar epidemiology and no-smoker enrichment

Frequently asked questions